Research progress of protein induced by vitamin K absence or antagonist II in liver transplantation for hepatocellular carcinoma.

Abstract

Hepatocellular carcinoma (HCC) is the most common pathologic type of primary liver cancer. Liver transplantation (LT) is a radical strategy for treating patients with early-stage HCC, which may lead to a better prognosis compared to hepatectomy and ablation. However, survival of patients who develop HCC recurrence after LT is short, and early recurrence is the most common cause of death. Thus, efficient biomarkers are also needed in LT to guide precision therapy to improve patient prognosis and 5-year survival. Protein induced by vitamin K absence or antagonist II (PIVKA-II) is an abnormal prothrombin that cannot activate coagulation, and it is significantly increased in patients with HCC, obstructive jaundice, and those taking vitamin K antagonists. Over the past decades, substantial progress has been made in the study of PIVKA-II in diagnosing, surveilling, and treating HCC, but its role in LT still needs to be elaborated. In this review, we focused on the role of PIVKA-II as a biomarker in LT for HCC, especially its relationship with clinicopathologic features, early recurrence, long-term survival, and donor-recipient selection.

• Authors: Zheyu Zhou, Qiaoyu Liu, Jinsong Liu, Wenwen Li, Shuya Cao, Jiawei Xu, Jun Chen, Xiaoliang Xu, Chaobo Chen
• Journal: Heliyon (Heliyon) Vol. 10 Issue 9 Pg. e30622 (May 15 2024) ISSN: 2405-8440 [Print] England
• PMID: 38726103 (Publication Type: Journal Article, Review)
• Copyright: © 2024 The Authors.